ExpreS2ion Biotech Holding AB (FRA:5JD0) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
ExpreS2ion Biotech Holding AB EBITDA Margin % Related Terms
ExpreS2ion Biotech Holding AB EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ExpreS2ion Biotech Holding AB EBITDA Margin % Chart
FRA:5JD0 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, ExpreS2ion Biotech Holding AB's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ExpreS2ion Biotech Holding AB EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ExpreS2ion Biotech Holding AB's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where ExpreS2ion Biotech Holding AB's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ExpreS2ion Biotech Holding AB (FRA:5JD0) has a EBITDA Margin % of -1,121.88% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on ExpreS2ion Biotech Holding AB and its competitors. According to the industry distribution chart, ExpreS2ion Biotech Holding AB ranks #769 out of 944 companies in the Biotechnology industry, placing it in the top 81.5%.
Is ExpreS2ion Biotech Holding AB's EBITDA Margin % too high?
ExpreS2ion Biotech Holding AB's current EBITDA Margin % is -1,121.88%. Based on the distribution chart, ExpreS2ion Biotech Holding AB ranks #769 out of 944 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, ExpreS2ion Biotech Holding AB has a GF Score™ of 41/100, reflecting its overall financial health beyond just this single metric.
How does ExpreS2ion Biotech Holding AB's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, ExpreS2ion Biotech Holding AB ranks #769 out of 944 companies for EBITDA Margin %. This places ExpreS2ion Biotech Holding AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on ExpreS2ion Biotech Holding AB and its competitors. ExpreS2ion Biotech Holding AB's current EBITDA Margin % is -1,121.88%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ExpreS2ion Biotech Holding AB stock overvalued right now?
ExpreS2ion Biotech Holding AB (FRA:5JD0) has a current EBITDA Margin % of -1,121.88%. The stock's GF Value™ is €0.08, compared to a current price of €0.04 — trading 53.5% below its estimated fair value. The current EBITDA Margin % is -1,121.88%. ExpreS2ion Biotech Holding AB's overall GF Score™ is 41/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For ExpreS2ion Biotech Holding AB (FRA:5JD0), the current EBITDA Margin % is -1,121.88% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ExpreS2ion Biotech Holding AB (FRA:5JD0) Overvalued in 2026?
Based on GuruFocus' analysis, ExpreS2ion Biotech Holding AB stock appears to be undervalued.
The current stock price of €0.04 is trading 53.5% below its estimated GF Value™ of €0.08.
Key valuation signals for FRA:5JD0:
EBITDA Margin %: -1,121.88%
GF Value™: €0.08 vs. price of €0.04 (53.5% below fair value)
No single metric tells the full story. See the FRA:5JD0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ExpreS2ion Biotech Holding AB Business Description
ExpreS2ion Biotech Holding AB is a biotechnology company that develops vaccines. It has developed a human clinical Phase III-validated technology platform, ExpreS2, for fast and efficient development and production of the active material in vaccines. The platform, under the brand GlycoX-S2, includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Its product pipeline comprises ES2B-C001, a HER2-VLP-based vaccine in development for human breast cancer therapy and several exploratory vaccine projects targeting pathways validated by commercial monoclonal antibody products. Geographically, the company operates in the Nordics region and also has a presence in other countries.
41GF Score
Get the complete analysis for FRA:5JD0
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:5JD0 has been successfully added to your 
